Immunicum intends to use its proprietary platform technology, enabling development of a broad spectrum of different immunotherapies, to form strategic alliances with suitable partners. The company aims to successfully complete clinical phase II trials and subsequently seek to partner with established actors in the pharmaceutical industry with which to complete clinical phase III trials and market the vaccine.